Enhancing Linkage to Hepatitis C Virus Treatment Following Pregnancy in Women Identified During Perinatal Care

Rachel L. Epstein,1,2 Carole Moloney,3 Jacob Garfinkel,4 Kelley Saia,4 Elisha M. Wachman,5 Sara Lodi,6 and Stephen I. Pelton2

Amid the current US opioid crisis, hepatitis C virus (HCV) infection rates continue to rise in young adults, including among pregnant women, yet few studies describe linkage to care and treatment in pregnant or postpartum women with HCV infection. We used electronic health record data to estimate HCV treatment rates for postpartum women before (January 2014–September 2016) and during (October 2016–March 2018) implementation of a maternal–infant HCV linkage program in combination with a multidisciplinary clinic to colocate mother and infant care. Using Poisson regression models, we compared HCV treatment initiation rates, adjusting for demographics, substance use, and treatment. From January 2014 through March 2018, 343 women who were HCV seropositive delivered at our institution. Of these, 95% completed HCV nucleic acid testing and 255 women had chronic HCV infection. Mean age was 30 years, 96% were publicly insured, and 94% had documented substance use. HCV treatment initiation increased from 28/164 (17.1%) women with chronic HCV infection in the preintervention period to 16/66 (24.2%) with the linkage-only intervention and 13/25 (52.0%) with the linkage intervention and colocated care. Adjusted analyses demonstrated that women delivering during the intervention period initiated HCV treatment at 2.40 times (95% confidence interval [CI], 1.10–5.25; linkage only) and 3.36 times (95% CI, 1.57–7.17; linkage and colocated care) the rate of women delivering preintervention. Women on buprenorphine had higher HCV treatment initiation rates compared with those on methadone (rate ratio, 2.10; 95% CI, 1.05–4.21).

Conclusion: HCV linkage to care and treatment rates improved in the setting of mother–infant linkage and colocated care interventions. Perinatal care may represent a critical venue to identify, link, and treat women for HCV infection to improve their own health and prevent transmission to subsequent pregnancies. (Hepatology Communications 2021;5:1543–1554).

The current opioid overdose crisis in the United States primarily affects young adults under age 40, half of whom are women of reproductive age.1,2 In association with increasing rates of injection drug use, hepatitis C virus (HCV) infection incidence continues to rise in the United States. Between 1999 and 2014, the number of pregnant women with diagnosed opioid use disorder (OUD) quadrupled from 1.5 to 6.5 per 1,000 delivery hospitalizations,3 and the number of deliveries affected by hepatitis C rose 5-fold over the same period to 29,000 affected deliveries in 2015.4,5

Until this year, the Centers for Disease Control and Prevention (CDC) recommended HCV testing during pregnancy only in women at high risk for HCV. These women are those identified with injection drug...
use; certain medical conditions, such as human immuno- 
nodeficiency virus (HIV); unregulated tattoos; or a 
known exposure; yet, as in HIV, data demonstrate 
that risk-based testing alone fails to identify HCV 
infections and halt transmission. The CDC 
recently responded with new guidance, consistent 
with 2018 guidance from national infectious diseases 
and liver societies, to recommend universal prena-
tal HCV testing. This change should help identify 
more women with undiagnosed HCV infection but 
also requires infrastructure to link identified women 
to HCV care and treatment. Although direct-acting 
antivirals (DAAs) have revolutionized HCV care with 
cure rates >95% in virtually all populations, only an 
estimated 37% of the 4.3 million individuals infected 
with HCV in the United States had been treated as 
of 2018. DAAs are not currently approved by the 
US Food and Drug Administration for use during 
pregnancy because data remain limited in this popu-
lation. Clinical trials are ongoing to test DAA safety 
and efficacy, and treatment during pregnancy may be 
a possibility in the future. Currently, women can 
be linked to HCV care for treatment after pregnancy 
and cessation of breastfeeding.

Linkage to HCV treatment from perinatal care 
could be a powerful strategy to enhance care contin-
uum follow-up for both women and their infants as 
women could be motivated to take charge of their 
family’s health at that time. Linking new moth-
ers to care could improve not only their own health 
through seeking cure but also follow-up for their 
HCV-exposed infant and prevent vertical trans-
mision in future pregnancies. Few studies describe 
HCV referral and treatment practices in women 
diagnosed with HCV during pregnancy, and 
only one describes HCV treatment in the DAA era, 
with improved treatment rates for a limited num-
ber of postpartum women compared to the general 
population.

In October 2016 at Boston Medical Center (BMC), 
an urban academic medical center serving a medically 
underserved population, we implemented a maternal-
infant HCV care linkage program alongside a multi-
disciplinary program to colocate maternal and infant 
primary and specialty care for women and families 
fected by substance use. The objective of this study 
was to compare linkage rates to HCV cure for women 
before and after implementation of these programs.

Participants and Methods

MATERNAL-INFANT LINKAGE TO CARE PROGRAM

The BMC is the largest safety-net hospital and 
prenatal care provider for women with substance use 
in New England. Approximately 120 women with 
OUD and 75 women with chronic HCV infection 
deliver annually at BMC. In October 2016, the pedi-
atries department initiated consultation from pedi-
atric infectious diseases for any postpartum woman 
with identified HCV antibody positivity. The con-
sultation, which continues to date, involves (1) nurse 
practitioner or physician review of the mother’s med-
ical chart, (2) maternal education on HCV treatment

Potential conflict of interest: Dr. Pelton consults, advises, and received grants from Pfizer; he advises and received grants from Merck and Sanofi Pasteur and consults and advises Sequirus. The other authors have nothing to report.

ARTICLE INFORMATION:

From the Department of Medicine, Section of Infectious Diseases; Department of Pediatrics, Section of Infectious Diseases, Boston University School of Medicine, Boston, MA, USA; Department of Obstetrics and Gynecology; Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.

ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:

Rachel L. Epstein, M.D., M.Sc.
Department of Medicine, Section of Infectious Diseases
Boston University School of Medicine
801 Massachusetts Avenue, Crosstown Building, 2nd Floor
Boston, MA 02118, USA
E-mail: Rachel.Epstein@bmc.org
Tel.: +1-617-414-7428
and transmission, and (3) active linkage to an HCV care clinician (any specialty, per maternal preference) for herself, if applicable, and to the pediatric infectious diseases program for follow-up of her exposed infant. The consulting team also works to link fathers to care, depending on privacy and availability. The active linkage involves maternal and infant appointment scheduling, appointment reminder calls or texts, and in-person reminders, if possible, during pediatric infectious diseases, primary care, or addiction care visits at BMC. HCV treatment occurs in both primary care and specialty clinics within the BMC health system, and multiple primary care clinics at BMC integrate HCV and addiction medicine care. Massachusetts removed restrictions to HCV state Medicaid treatment policies in August 2016 and since then has not restricted HCV treatment by fibrosis stage, abstinence criteria, or provider specialty.\(^{(22)}\)

**MULTIDISCIPLINARY COLOCATED CARE CLINIC**

In July 2017, in response to the many BMC families affected by addiction and limited success with engagement of postpartum women back to primary, HCV, or other specialty care for themselves or their infants,\(^{(17,23)}\) the pediatric department initiated a multidisciplinary clinic to colocate postpartum maternal and infant care, the Supporting Our Families through Addiction and Recovery (SOFAR) program.\(^{(24)}\) This program combines under one roof intensive medical and sociobehavioral support to families experiencing addiction, including infant primary care, developmental and behavioral pediatrics, infectious diseases, psychiatric and addiction care for mothers, social work, case management, and peer navigation support. The colocated care is designed to minimize the number of postpartum appointments mothers have for both themselves and their infants to maximize follow-up for the entire family. The program began in July 2017 and is open to all infants born with prenatal substance-use exposure followed at BMC. The program is designed for both maternal and infant care but continues to follow the infants if the mother seeks care elsewhere.

Both initiatives required departmental commitment and hospital funding to support a specialized nurse practitioner for the HCV nursery consult and a part-time program coordinator for SOFAR. For both interventions, lead pediatricians helped with program design and staff education for the nursery, neonatal intensive care, and pediatrics units about the respective programs and how to place consults to initiate each.

**DATA COLLECTION**

In this single-center retrospective cohort study, we analyzed data for all women identified as HCV antibody positive by electronic health record (EHR) laboratory data who delivered a live birth at BMC from January 2014 to March 2018. This time period allowed evaluation of deliveries for 2 years before the intervention but still during the DAA era. We collected laboratory and medication data, problem lists, social history data fields, demographics, and visit data through the EHR-based BMC Clinical Data Warehouse through June 2019. This allowed at least 15 months follow-up after delivery as HCV treatment is not recommended concurrent with pregnancy or breastfeeding. We also reviewed pediatric infectious diseases consults conducted for perinatal HCV consultation during the intervention period to ensure inclusion of women who may have had HCV testing performed outside the BMC EHR. Finally, in October 2020, we manually reviewed charts of women who were prescribed DAAs but did not have laboratory evidence of cure by June 2019 to better determine cure rate and adequacy of DAA prescription as a linkage marker.

**CATEGORIZATION OF OUD**

We combined the following three data sources to categorize substance use: the EHR problem list (International Classification of Disease, Ninth or Tenth Revision [mapped to Tenth Revision] codes for diagnosed opioid [F11], cannabis [F12], sedative, hypnotic, or anxiolytic [F13], cocaine [F14], other stimulant [F15], hallucinogen [F16], inhalant [F18], or other substance [F19] abuse or dependence); social history section (templated choices and free text of clinician-recorded individual substances); and medication list (presence of methadone, buprenorphine, or buprenorphine/naloxone). We included substance use occurring before or during pregnancy up through delivery and recorded the medication prescribed closest to delivery. We defined substance use as a categorical variable as
opioid use alone (without unprescribed stimulant use), opioid and unprescribed stimulant use together, other substance use, or no substance use identified.

OUTCOME DEFINITIONS

We used descriptive statistics to characterize the sample and the HCV care cascade, including mean time from delivery to the first recorded HCV treatment prescription. We defined the HCV care cascade as follows: (1) positive HCV antibody testing (any time before delivery); (2) HCV nucleic acid (RNA) testing completed to test for chronic HCV infection; (3) detectable HCV RNA before or during pregnancy, without interim negative HCV RNA testing (through either spontaneous clearance or HCV treatment); (4) HCV genotype testing completed; (5) HCV treatment initiation, evidenced by prescription order in the EHR for a DAA; and (6) HCV cure (sustained virologic response [SVR]), meaning undetectable HCV RNA ≥12 weeks after treatment completion.

We defined treatment initiation as our primary outcome as it confirms linkage to HCV care, which was the objective of the maternal HCV linkage program.

INCLUSION CRITERIA

For the linkage to cure analysis, we included only women with current chronic HCV infection because women who have cleared virus spontaneously do not require treatment. For women with more than one eligible pregnancy, we included only the most recent pregnancy so as not to count the second pregnancy toward time she may have linked and to better capture care behavior since more recent DAA approvals and availability.

STATISTICAL ANALYSIS

We summed person time between delivery and either HCV treatment initiation (primary outcome) or loss to follow-up (censoring event) for each woman by quarter. For the analysis, we included only women who were viremic at pregnancy start or during pregnancy and who had at least one follow-up care visit after delivery within our institution in infectious diseases, gastroenterology, addiction medicine, or primary care. We restricted the sample in this way to focus on women who continued to seek care at BMC after delivery as it was more likely we would accurately capture their follow-up and less likely they would be treated for HCV at an outside institution. Each woman contributed person time (during which she was eligible to be treated) from the latest of her delivery date or July 1, 2016, when Massachusetts Medicaid HCV treatment restrictions were removed, until the earliest date of (1) treatment start date, if treated, or (2) last visit date at BMC before the end of the study (June 2019). Intervention group served as the primary predictor as follows: those who delivered preintervention, those who received an HCV consult only (linkage), and those who received both an HCV linkage consult and participated in the mother–baby multidisciplinary clinic (linkage and SOFAR/colocated care).

We used Poisson models to estimate and compare HCV treatment initiation rates for women delivering before and after intervention. Univariable models evaluated the following covariates that clinically we expected to affect HCV treatment rates: age (continuous), race/ethnicity, substance use (categorical variable described above encompassing problem list, medication, and social history data), opioid agonist medication at delivery (methadone, buprenorphine, or none), and smoking status at delivery. We did not include insurance status or language spoken as covariates due to the predominance of Medicaid insurance and English as a primary language (Table 1). In the final adjusted models, we included age a priori and all variables with P < 0.1 in univariable analyses. Opioid agonist treatment was strongly associated with substance use category at delivery, so separate multivariable models included either substance use or opioid agonist treatment to evaluate effects of each. All analyses were performed in SAS, version 9.4 (Cary, NC).

This study was approved by the Boston University Medical Campus Institutional Review Board as exempt research as it involved chart review only.

Results

The cohort included 343 women who were HCV seropositive and who delivered at BMC from January 2014 through March 2018. Of these, 255 women had known HCV viremia either during or after pregnancy and were included in the analysis. The distribution of characteristics was similar before and during intervention periods. The majority of women had substance
| Variable                                                                 | Preintervention n = 164 (%)† | Linkage n = 66 (%)† | Linkage + SOFAR n = 25 (%)† |
|-------------------------------------------------------------------------|-------------------------------|---------------------|-----------------------------|
| Age at delivery, years as mean (SD, range)                              | 29.8 (4.8, 20-40)            | 29.8 (4.9, 20-40)   | 30.8 (4.4, 24-39)           |
| Race/ethnicity                                                          |                               |                     |                             |
| Black non-Hispanic                                                     | 20 (12.2)                     | 6 (9.1)             | 0                           |
| Hispanic or Latino                                                     | 11 (6.7)                      | 5 (7.6)             | 1 (4.0)                     |
| White non-Hispanic                                                     | 127 (77.4)                    | 52 (79.8)           | 23 (92.0)                   |
| Other‡                                                                | 1 (0.6)                       | 0                   | 0                           |
| Declined/unknown                                                       | 5 (2.9)                       | 3 (4.6)             | 1 (4.0)                     |
| Primary language spoken                                                |                               |                     |                             |
| English                                                                | 158 (96.9)                    | 64 (97.0)           | 25 (100.0)                  |
| Other                                                                  | 5 (3.1)                       | 2 (2.2)             | 0                           |
| Insurance type                                                          |                               |                     |                             |
| Medicaid                                                               | 155 (94.5)                    | 65 (98.5)           | 24 (96.0)                   |
| Commercial                                                             | 5 (3.0)                       | 0                   | 0                           |
| Free care or other                                                     | 2 (1.2)                       | 0                   | 0                           |
| Missing/Unknown                                                        | 2 (1.2)                       | 1 (1.5)             | 1 (4.0)                     |
| Marital status                                                         |                               |                     |                             |
| Single                                                                 | 143 (87.7)                    | 58 (87.9)           | 19 (76.0)                   |
| Married                                                                | 10 (6.1)                      | 3 (4.6)             | 3 (12.0)                    |
| Previously married                                                     | 7 (4.3)                       | 4 (6.1)             | 3 (12.0)                    |
| Other/unknown                                                          | 4 (2.4)                       | 1 (1.5)             | 0                           |
| Tobacco use, at delivery                                               |                               |                     |                             |
| Current                                                                | 107 (65.2)                    | 43 (65.2)           | 20 (80.0)                   |
| Prior                                                                  | 19 (11.6)                     | 11 (16.7)           | 5 (20.0)                    |
| Never                                                                  | 14 (8.5)                      | 11 (16.7)           | 0                           |
| Unknown                                                                | 24 (14.6)                     | 1 (1.5)             | 0                           |
| Any identified substance use                                            |                               |                     |                             |
| Yes                                                                    | 155 (94.5)                    | 59 (89.4)           | 25 (100)                    |
| No                                                                     | 9 (5.5)                       | 7 (10.6)            | 0                           |
| Diagnosed substance abuse or dependence, by ICD-9/10 code§             |                               |                     |                             |
| Any                                                                    | 132 (80.5)                    | 54 (81.8)           | 24 (96.0)                   |
| Opioid                                                                 | 89 (54.3)                     | 32 (48.5)           | 22 (88.0)                   |
| Cocaine, amphetamines, or methamphetamines                             | 24 (14.6)                     | 4 (6.1)             | 4 (16.0)                    |
| Cannabis                                                               | 1 (0.6)                       | 0                   | 1 (4.0)                     |
| Other§                                                                 | 92 (56.1)                     | 42 (63.6)           | 21 (84.0)                   |
| Drug use recorded in social history                                     |                               |                     |                             |
| Any                                                                    | 96 (58.5)                     | 36 (54.6)           | 17 (68.0)                   |
| Any documented intravenous drug use                                     | 84 (51.2)                     | 34 (51.5)           | 16 (64.0)                   |
| Cocaine, amphetamines, or methamphetamines                             | 42 (25.6)                     | 18 (27.3)           | 10 (40.0)                   |
| Heroin or fentanyl                                                     | 81 (49.4)                     | 34 (51.5)           | 16 (64.0)                   |
| Other opioids                                                          | 11 (6.7)                      | 3 (4.6)             | 2 (8.0)                     |
| Marijuana                                                              | 24 (14.6)                     | 3 (4.6)             | 3 (12.0)                    |
| Other¶                                                                | 24 (14.6)                     | 3 (4.6)             | 3 (12.0)                    |
| Medication for OUD, at delivery                                        |                               |                     |                             |
| None                                                                   | 32 (19.5)                     | 14 (21.2)           | 5 (20.0)                    |
use documented in the problem list, medication list or social history section (155/164 [94.5%] of women who delivered pre-intervention, 59/66 (89.4%) in linkage alone and 25/25 (100%) in linkage plus SOFAR) had substance use documented in the problem list, medication list, or social history section. Opioid use alone was most common, in 93/164 (56.7%) women before and 49/91 (53.8%) women during the intervention period. Concurrent opioid and unprescribed stimulant (cocaine, amphetamine, or methamphetamine) use was also frequently reported, particularly among individuals in the linkage plus SOFAR group (52.0%), and approximately half had documented injection drug use in each group (Table 1). At delivery, 132/164 (80.5%) women before and 72 (79.1%) women during the intervention were prescribed opioid agonist therapy, with more women on methadone (85/164 [51.8%] before and 42/91 [46.1%] during intervention) compared with buprenorphine (47/164 [28.7%] vs. 30/91 [33.0%], respectively).

### HCV CARE CASCADE

Across both periods, 95% of women who were seropositive had RNA testing completed, and 74% of women who were seropositive were diagnosed with chronic HCV infection (Fig. 1). Sixteen women (6.3%) were likely (previous negative HCV testing) and 45/255 (17.6%) women were possibly (no previous laboratories documented) newly diagnosed with chronic HCV infection during pregnancy. The majority of women who were viremic (75.0% preintervention, 83.3% who received the linkage intervention only, and 92.0% with the linkage intervention and SOFAR) had genotype testing completed, and 28 (17.1%) women who were viremic before intervention, 16 (24.2%) with the linkage intervention only, and 13 (52.0%) with the linkage intervention and SOFAR had evidence of HCV treatment initiation (Fig. 1). By October 2020, 24/28 (85.7%) women preintervention, 13/16 (81.2%) women with the linkage intervention, and 9/13 (69.2%) women with the intervention and SOFAR who were prescribed therapy had evidence of cure (SVR). Chart review revealed that those who did not achieve SVR either never started treatment (2 women before and 2 women during the intervention, including 1 who spontaneously cleared during a 6-month delay between prescription order and representation to care) or were lost to follow-up before SVR laboratories were obtained (2 preintervention and 5 during the intervention). Preintervention,

### TABLE 1. Continued

| Variable | Preintervention n = 164 (%)† | Linkage n = 66 (%)† | Linkage + SOFAR n = 25 (%)† |
|----------|-----------------------------|---------------------|-----------------------------|
| Methadone | 85 (51.8) | 31 (47.0) | 11 (44.0) |
| Buprenorphine§ | 47 (28.7) | 21 (31.8) | 19 (36.0) |
| Combined substance use categorization** | | | |
| Opioid use alone | 93 (56.7) | 37 (56.1) | 12 (48.0) |
| Opioid and nonprescribed stimulant use | 58 (35.4) | 19 (28.8) | 13 (52.0) |
| Other substance use only | 4 (2.4) | 3 (4.6) | 0 |
| None | 9 (5.5) | 7 (10.6) | 0 |
| HCV-treating physician specialty†† | | | |
| Primary care/addiction medicine | 14 (50.0) | 10 (62.5) | 9 (69.2) |
| Gastroenterology | 9 (32.1) | 3 (18.8) | 2 (15.4) |
| Infectious diseases | 5 (17.9) | 3 (18.8) | 2 (15.4) |

*Before implementation was January 2014-September 2016; during implementation was October 2016-March 2018.
†n (%) unless otherwise indicated.
‡Asian, American Indian, Alaska Native, or Pacific Islander.
§As recorded in the maternal problem list, not mutually exclusive categories.
‖Sedatives, hypnotics, hallucinogens, inhalants, or other psychoactive substances.
¶Benzodiazepine, barbiturate, LSD, MDMA, marijuana, or psilocybin.
#Buprenorphine alone or combination buprenorphine/naloxone.
**Incorporates data from each category above (ICD-9/10 codes, social history, and medications for OUD).
††Percentages are out of the 28 women in the preintervention period and 28 in the intervention period who had HCV treatment initiation.

Abbreviations: ICD-9/10, International Classification of Diseases, Ninth or Tenth Revision; LSD, lysergic acid diethylamide; MDMA, 3,4-methylenedioxymethamphetamine.
primary care or addiction clinicians wrote 50% of DAA prescriptions, and during the intervention this increased to 19/29 (65.5%) of prescriptions (Table 1).

**SUBGROUP WITH CONTINUED FOLLOW-UP CARE AT BMC**

In the cohort of women with BMC follow-up postpregnancy, characteristics were similar before and during intervention periods, with two exceptions. Buprenorphine treatment for OUD was more common during the intervention period (44.0% linkage group, 33.3% linkage plus SOFAR group vs. 27.0% preintervention group) as methadone maintenance therapy became less frequent (40.0% during linkage intervention, 45.5% in linkage plus SOFAR vs. 57.1% preintervention) (Table 2). Women who delivered preintervention also had an overall longer BMC follow-up observed (mean, 593 vs. 326 days) because of the greater observation time in the study with a specified end date. Mean time between delivery and HCV treatment initiation decreased from 336 (SD, 228) days for women delivering preintervention to 247 (SD, 100; linkage alone) and 243 (SD, 183; linkage plus SOFAR) days for women delivering during the intervention period. Of the 70 women who were not treated, 38 (54.3%) were still in care during the last study year. For those lost to follow-up before the end of the study (n = 32), mean time in care postpartum was 331 (SD, 201; range, 26-743) days.

**REGRESSION ANALYSIS**

In univariate analysis, women received HCV treatment in the linkage group at 3.23 times (95% confidence interval [CI], 1.54-6.76) and in the linkage plus SOFAR group at 3.26 times (95% CI, 1.60-7.04) the rate of women preintervention (Table 3). Buprenorphine compared with methadone opioid agonist therapy and opioid use alone compared with opioid and unprescribed stimulant use were also associated with increased treatment rates. In the model adjusted for substance use, delivery during intervention compared with the preintervention period was
associated with an increased treatment rate (rate ratio [RR], 2.87; 95% CI, 1.34-6.18 for the linkage group; RR, 3.89; 95% CI, 1.83-8.26 for the linkage plus SOFAR group). Results were similar after adjusting for opioid agonist therapy rather than substance use (Table 3), and buprenorphine prescription at delivery was also associated with increased HCV treatment compared to methadone (RR, 2.10; 95% CI, 1.05-4.21).

Discussion

We describe a linkage intervention and a multidisciplinary clinic colocating mother and infant care to identify peripartum women eligible for HCV treatment postdelivery and engage them in HCV care and treatment after pregnancy and breastfeeding. Adjusting for follow-up time, age, substance use, and opioid agonist treatment, HCV treatment initiation increased for women delivering after intervention implementation. For women who continued to seek care at our institution postpregnancy, those delivering during the linkage intervention had over 2 times the rate of HCV treatment initiation and women exposed to both the linkage intervention and colocated care had over 3 times the rate of HCV treatment initiation compared with women delivering preintervention.

This is among the first studies to examine HCV treatment rates and linkage to care interventions in women identified during pregnancy. Nearly all women who were seropositive had HCV RNA testing, aided by reflex testing implementation (all positive-HCV antibody testing is automatically reflexed to RNA and genotype testing) initiated in August 2016. Approximately 75% of women who were HCV

### Table 2. Characteristics of Women with HCV Infection (Viremia) Who Delivered at BMC January 2014-March 2018 with Continued Follow-up Postpartum Within the Health System Through at Least July 2016

| Variable                          | Preintervention* n = 63 (%)† | Linkage n = 25 (%)‡ | Linkage + SOFAR n = 24 (%)‡ |
|----------------------------------|------------------------------|---------------------|-----------------------------|
| **Age in years, mean (range)**   | 30.1 (20-40)                 | 29.8 (20-38)        | 30.9 (24-39)                |
| **Age (years)**                  |                              |                     |                             |
| <25                              | 5 (7.9)                      | 2 (8.0)             | 2 (8.3)                     |
| 25-35                            | 47 (74.6)                    | 17 (68.0)           | 17 (70.8)                   |
| ≥35                              | 11 (17.5)                    | 6 (24.0)            | 5 (20.8)                    |
| **Race/ethnicity**               |                              |                     |                             |
| White non-Hispanic               | 48 (76.2)                    | 22 (88.0)           | 22 (91.7)                   |
| Other                            | 15 (23.8)                    | 3 (12.0)            | 2 (8.3)                     |
| **Current tobacco use‡**         |                              |                     |                             |
| Yes                              | 43 (68.2)                    | 17 (68.0)           | 18 (75.0)                   |
| No                               | 20 (31.8)                    | 8 (32.0)            | 6 (25.0)                    |
| **Substance use‡**               |                              |                     |                             |
| Opioid use only                  | 30 (47.6)                    | 18 (59.2)           | 11 (45.8)                   |
| Opioid and nonprescribed stimulant use | 31 (49.2) | 5 (20.0) | 13 (54.2) |
| Other or none                    | 2 (3.2)                      | 2 (8.0)             | 0                           |
| **Opioid agonist medication†**   |                              |                     |                             |
| None                             | 10 (15.9)                    | 4 (16.0)            | 5 (20.8)                    |
| Buprenorphine                    | 17 (27.0)                    | 11 (44.0)           | 8 (33.3)                    |
| Methadone                        | 36 (57.1)                    | 10 (40.0)           | 11 (45.8)                   |
| Mean follow-up time, days§ (SD)  | 593(362)                     | 326 (188)           | 327 (196)                   |

*Preintervention period, January 2014-September 2016; intervention period, October 2016-March 2018.
†n (%) unless otherwise indicated.
‡At time of delivery, as noted in the social history section, problem list, or medication list.
§Follow-up time denotes days from delivery through first of either HCV treatment or last recorded BMC primary/addiction care, gastroenterology, or infectious diseases visits completed.
seropositive in this study had ongoing viremia, consistent with the literature-reported spontaneous acute clearance rate (26%) and with very few women having received treatment before delivery. With recent CDC guidelines to screen all women during each pregnancy, infrastructure must be created to link women identified to have chronic HCV infection to HCV cure after delivery. Increasing HCV treatment rates for women identified during pregnancy imparts benefits not just to the women treated as it can also prevent vertical transmission in any future pregnancies and horizontal transmission with further risk behavior.

This study has several limitations. Data are limited by availability through a single medical center; treatment received elsewhere is not captured. However, we restricted the primary analysis cohort to individuals continuing to receive primary or HCV-treating specialty care at our institution to minimize bias introduced from missing data for women treated elsewhere. This restricts our study to a population with continued care-seeking behaviors and therefore may be less generalizable; however, it allows for more accurate person-time measurement and more accurate comparisons between the selected groups. As a retrospective study with a historic control group, findings may be confounded by time-related variables, such as new drug approvals, increased state Medicaid treatment eligibility criteria, other linkage initiatives, and improved provider education over the study period. To minimize these time-related confounding effects, we analyzed women in all groups by quarter over the same calendar time starting from July 2016 when Massachusetts removed Medicaid HCV treatment restrictions. We also restricted our population to

**Table 3. HCV Treatment Initiation Rates in Women With HCV Infection (Viremia) Who Delivered at BMC January 2014-March 2018 With Continued Follow-Up Postpartum Within the Health System Through at Least July 2016**

| Variable | Treated (n = 42)* | Not Treated (n = 70)* | Unadjusted Rate Ratio† (95% CI) | Adjusted Rate Ratio‡ (95% CI) | Adjusted Rate Ratio§ (95% CI) |
|----------|------------------|----------------------|--------------------------------|-------------------------------|-------------------------------|
| **Intervention period** | | | | | |
| Preintervention | 17 (27.0) | 46 (73.0) | Ref. | Ref. | Ref. |
| Linkage | 13 (52.0) | 12 (48.0) | 3.23 (1.54, 6.76) | 2.87 (1.34, 6.18) | 2.40 (1.10, 5.25) |
| Linkage + SOFAR | 12 (50.0) | 12 (50.0) | 3.26 (1.60, 7.04) | 3.89 (1.83, 8.26) | 3.36 (1.57, 7.17) |
| **Age in years, mean (SD; range)** | 29.3 (4.1; 20-36) | 30.8 (4.6; 21-40) | 0.93 (0.87, 1.01) | 0.92 (0.86, 0.99) | 0.92 (0.86, 0.99) |
| **Race/ethnicity** | | | | | |
| White non-Hispanic | 36 (39.1) | 56 (60.9) | 1.49 (0.63, 3.55) | — | — |
| Other | 6 (30.0) | 14 (70.0) | Ref. | — | — |
| **Current tobacco use** | | | | | |
| Nonsmoker | 11 (32.4) | 23 (67.6) | Ref. | — | — |
| Smoker | 31 (39.7) | 47 (60.3) | 1.36 (0.68, 2.71) | — | — |
| **Substance use** | | | | | |
| Opioid use only | 28 (47.5) | 31 (52.5) | Ref. | Ref. | — |
| Opioid and non-prescribed stimulant use | 13 (26.5) | 36 (73.5) | 0.46 (0.23, 0.89) | 0.56 (0.28, 1.12) | — |
| Other | 1 (25.0) | 1 (75.0) | 0.40 (0.05, 2.92) | 0.32 (0.04, 2.44) | — |
| None | 0 (0) | 0 (0) | — | — | — |
| **Opioid agonist medication** | | | | | |
| Buprenorphine | 20 (55.6) | 16 (44.4) | 2.71 (1.40, 5.23) | — | 2.10 (1.05, 4.21) |
| Methadone | 17 (29.8) | 40 (70.2) | Ref. | — | Ref. |
| None | 5 (26.3) | 14 (73.7) | 0.85 (0.31, 2.33) | — | 0.80 (0.29, 2.19) |

*Data show n (%) unless otherwise indicated.
†CIs that do not overlap the null value of RR = 1 are shown in bold.
‡Adjusted for age a priori and all variables with P < 0.1 in unadjusted analysis, excluding opioid agonist medication at delivery.
§Adjusted for age a priori and all variables with P < 0.1 in unadjusted analysis, excluding substance use at delivery.
||At the time of delivery, as noted in social history, problem list, or medication list.
Abbreviation: Ref., reference.
women “in care” to avoid biasing the preintervention population estimates by assuming all women were still in care at BMC years after delivery.

At least 98% of women in this study were insured at delivery and likely had continued health insurance postpartum. We realize this is not the case in all countries or US states and limits generalizability. Initiatives to enroll participants in health insurance coverage postpartum could be coupled with these interventions to improve both HCV and general health care for women and families. Treatment during pregnancy could be an option in the future, or treatment immediately postpartum for women who do not breastfeed (depending on duration of postpartum coverage) could be an option to capture women with limited insurance options postpartum. Our institution plans to pilot an obstetrician-led program for obstetric and family medicine clinicians to treat HCV during an extended 12-month postpartum and recovery care model to further reduce linkage to care barriers.

The limited number of women in each intervention group with continued BMC follow-up and overlap between the linkage program and colocated care clinic limited our ability to isolate the effects of either intervention from the other. A few women were discharged before the linkage consultation, which may have biased results toward the null hypothesis, but we did not exclude these women as the linkage intervention extended to touchpoints with women during pediatric and colocated care appointments. We also cannot isolate whether the intervention itself or the overall interaction with prenatal care during a period of treatment availability accounted for the results. Either explanation, however, highlights perinatal care as an effective venue to screen women with HCV and link them to care. Finally, we were unable to ascertain the reasons women declined or delayed HCV treatment. In clinical practice, we observe the competing priorities of maintaining recovery and caring for infants in the postpartum period in addition to transportation and other logistic hurdles. The active linkage and colocated care interventions in this study aimed to decrease the hurdle of finding a treating provider and of attending additional appointments. They were successful for many but not all women in this study, and research to understand additional barriers to HCV treatment for postpartum women and solutions to overcome them is needed.

Treatment initiation rates and time to treatment initiation (mean was 8 months during the intervention period) were equal to or higher than literature-reported rates in most observational and linkage studies (excluding those offering direct treatment in the same clinic). Given lower breastfeeding rates in this population, other factors, such as insurance prior authorizations (and their required laboratory work-up) and delays in obtaining appointments, likely influenced observed delays in treatment, but most women who initiated treatment did so <1 year postdelivery. SVR rates were relatively high as well, although subject to loss to follow-up, similar to rates observed in real-world demonstration studies. Chart review did not reveal evidence of treatment failure in those patients, but we cannot be certain; further studies into treatment adherence are warranted in this population.

Over 90% of women infected with HCV in this study had chart evidence of current or prior opioid use or misuse. These results are consistent with recent CDC data indicating that the majority of pregnant women with HCV infection have diagnosed OUD. Buprenorphine treatment and absence of polysubstance use were associated with increased treatment rates, and a high percentage of women were treated in primary care with integrated addiction medicine programs (64% during the intervention). Demonstration studies reveal high HCV treatment efficacy in populations who inject drugs, particularly when treatment is offered in the same location they receive other care or services. However, HCV treatment is not universally offered in OUD treatment programs, and many states continue to restrict the use of HCV treatments for individuals with ongoing or recent substance use. Although most states have made great strides in reducing barriers to HCV treatment, 27 state Medicaid programs still maintain restrictions by disease stage, concurrent substance use, or provider specialty. These restrictions pose significant obstacles to HCV elimination, particularly in women of reproductive age who are likely to have recent substance use and are unlikely to have significant liver disease. In order to translate universal prenatal HCV testing recommendations into treatment as prevention and progress toward HCV elimination, reproductive age women must have access to HCV cure.

Linking women to HCV cure is just one step in the HCV continuum of care and must be coupled with addiction management during pregnancy,
postpartum treatment programs, and recovery support for the majority of women with coexisting substance use. Colocating care for HCV and substance use treatment is effective, (31,33,34) and combining this with infant care could prove an even stronger intervention for this population. Furthermore, work to link fathers to both HCV and addiction care can help improve health for the entire family and decrease the likelihood of reinfection. The World Health Organization (WHO) 2030 HCV global elimination targets include ensuring 80% of eligible individuals are treated to help meet a 90% reduction in incidence and 65% reduction in liver mortality. (35) Following the role testing and treatment of pregnant women has played in the HIV epidemic, screening pregnant women for HCV, engaging them in care, treating them to prevent exposure in subsequent pregnancies, and diagnosing and curing infected infants could be key measures to help achieve these goals. Our findings provide evidence that a program beginning in prenatal care and extending to a postpartum multidisciplinary program can successfully increase treatment initiation rates in women with HCV infection initiating HCV treatment. This intervention provides a framework on which health systems can build prenatal HCV testing to advance toward WHO HCV elimination goals.

Acknowledgment: We thank all the patients and clinical staff involved in the implementation of the HCV linkage program and the SOFAR clinic and we thank Linda Rosen of the BMC Clinical Data Warehouse.

REFERENCES

1) Wilson N, Karissa M, Seth P, Smith HI, Davis N. Drug and opioid-involved overdose deaths—United States, 2017-2018. MMWR Morb Mortal Wkly Rep 2020;69:290-297.

2) Kozhimannil KB, Graves AJ, Jarlenski M, Kennedy-Hendricks A, Gollust S, Barry CL. Non-medical opioid use and sources of opioids among pregnant and non-pregnant reproductive-aged women. Drug Alcohol Depend 2017;174:201-208.

3) Haight SC, Ko JY, Tong VT, Bohm MK, Callaghan WM. Opioid use disorder documented at delivery hospitalization—United States, 1999-2014. Morb Mortal Wkly Rep 2018;67:845-849.

4) Ko JY, Haight SC, Schillie SF, Bohm MK, Dierz PM. National trends in hepatitis C infection by opioid use disorder status among pregnant women at delivery hospitalization—United States, 2000-2015. MMWR Morb Mortal Wkly Rep 2019;68:833-838.

5) Ly KN, Jiles RB, Teshale EH, Foster MA, Pesano RL, Holmberg SD. Hepatitis C virus infection among reproductive-aged women and children in the United States, 2006 to 2014. Ann Intern Med 2017;166:775-782.

6) Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo C-G, et al.; Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61:1-32. Erratum in: MMWR Recomm Rep. 2012;61:886.

7) Branson BM, Handsfield HH, Lampe MA, Jansen RS, Taylor AW, Lysy SB, et al.; Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55:1-17.

8) Rose M, Myers J, Evans J, Prince A, Espinosa C. Hepatitis C virus risk-based vs. universal screening among pregnant women: implementation and cost-effectiveness analysis [Abstract]. Hepatology 2018;68(Suppl. 1):A87.

9) Warungu W, Mhamma MJ, Kumar D, Abubali N. Hepatitis C virus universal screening versus risk based selective screening during pregnancy. J Neonatal-Perinatal Med 2015;8:371-378.

10) Kuncio DE, Newbern EC, Fernandez-Viña MH, Herdman B, Johnson CC, Viner KM. Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system. J Urban Health 2015;92:379-386.

11) AASLD-IDSA. HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018;67:1477-1492.

12) Schillie S, Wester C, Osborne M, Wosowskii L, Ryerson AB. CDC recommendations for hepatitis C screening among adults—United States, 2020. MMWR Recomm Rep 2020;69:1-17.

13) Chhatwal J, Chen Q, Betha ED, Hur C, Spaulding AC, Kanwal F. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Aliment Pharmacol Ther 2019;50:66-74.

14) Jhaiveri R, Broder T, Bhattacharya D, Peters MG, Kim AJ, Jonas MM. Universal screening of pregnant women for hepatitis C: the time is now. Cln Infect Dis 2018;67:1493-1497.

15) Chappell CA, Scarsi KK, Kirby BJ, Suri V, Gaggar A, Bogen DL, et al. Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase I pharmacokinetic study. Lancet Microbe 2020;1:e200-e208.

16) Larsen A, Magasana V, Dinh T-H, Ngandu N, Lombard C, Chypirp M, et al. Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa. BMC Infect Dis 2019;19(Suppl. 1):789.

17) Epstein RL, Sabharwal V, Wachman EM, Saia KA, Vellozzi C, Harir S, et al. Perinatal transmission of hepatitis C virus: defining the cascade of care. J Pediatr 2018;203:34-40.e1.

18) Krans EE, Zickmund SL, Rustgi VK, Park SY, Dunn SL, Schwarz EB. Screening and evaluation of hepatitis C virus infection in pregnant women on opioid maintenance therapy: a retrospective cohort study. Subst Abuse 2016;37:88-95.

19) Page K, Leeman L, Bishop S, Cano S, Bakherina LN. Hepatitis C cascade of care among pregnant women on opioid agonist pharmacotherapy attending a comprehensive prenatal program. Matern Child Health J 2017;1778-1783.

20) Kim NJ, Holguin D, Bush D, Khalili M. Hepatitis C screening in an underserved U.S. cohort of reproductive age women. Hepatol Commun 2019;3:1183-1190.

21) Boudova S, Mark K, El-Kamary SS. Risk-based hepatitis C screening in pregnancy is less reliable than universal screening: a retrospective chart review. Open Forum Infect Dis 2018;5:ofy043.

22) National Viral Hepatitis Roundtable and the Center for Health Law and Policy Innovation. Hepatitis C: state of Medicaid access; 2019. https://stateofhepc.org. Accessed November 2020.

23) Schiff DM, Nielsen T, Terplan M, Hood M, Bernson D, Diop H, et al. Fatal and nonfatal overdose among pregnant and...
postpartum women in Massachusetts. Obstet Gynecol 2018;132:466-474.
24) Stulac S, Bair-Merritt M, Wachman EM, Augustyn M, Howard C, Madoor N, et al. Children and families of the opioid epidemic: under the radar. Curr Probl Pediatr Adolesc Health Care 2019;49:100637.
25) Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006;13:34-41.
26) United States Census Bureau. Health insurance coverage in the United States: 2019. https://www.census.gov/library/publications/2020/demo/p60-271.html. Published September 15, 2020. Accessed March 2021.
27) Assoumou SA, Wang J, Nolen S, Eftekhar Yazd G, Mayer KH, Puro J, et al. HCV testing and treatment in a national sample of US federally qualified health centers during the opioid epidemic. J Gen Intern Med 2020;35:1477-1483.
28) Coyle C, Moorman AC, Bartholomew T, Klein G, Kwakwa H, Mehta SH, et al. The hepatitis C virus care continuum: linkage to hepatitis C virus care and treatment among patients at an urban health network, Philadelphia, PA. Hepatology 2019;70:476-486.
29) Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, et al. The population level cascade of care for hepatitis C in British Columbia, Canada: the BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine 2016;12:189-195.
30) Schiff DM, Wachman EM, Philipp B, Joseph K, Shrestha H, Taveras EM, et al. Examination of hospital, maternal, and infant characteristics associated with breastfeeding initiation and continuation among opioid-exposed mother-infant dyads. Breastfeed Med 2018;13:266-274.
31) Bartholomew TS, Grosgebauer K, Huynh K, Cos T. Integration of hepatitis C treatment in a primary care federally qualified health center, Philadelphia, Pennsylvania, 2015-2017. Infect Dis (Auckl) 2019;12:117863719841381.
32) Janjua NZ, Darvishian M, Wong S, Yu A, Rossi C, Ramji A, et al.; British Columbia Hepatitis Testers Cohort Team. Effectiveness of ledipasvir/sofosbuvir and sofosbuvir/velpatasvir in people who inject drugs and/or those in opioid agonist therapy. Hepatol Commun 2019;3:478-492.
33) Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Eftekhar Yazd G, Stein MD, et al. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. Int J Drug Policy 2019;72:160-168.
34) Rich KM, Bia J, Altice FL, Feinberg J. Integrated models of care for individuals with opioid use disorder: how do we prevent HIV and HCV? Curr HIV/AIDS Rep 2018;15:266-275.
35) World Health Organization. Global hepatitis report, 2017. https://www.who.int/publications/i/item/global-hepatitis-report-2017. Published April 2017. Accessed November 2020.